This study aimed to detect the protein expression of HA117 in pediatric solid tumors. Immunohistochemistry was performed to detect the expression of HA117 and P-gp in pediatric solid tumors. In Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), nephroblastoma (WT), and neuroblastoma (NB), the positive expression rate of HA117 was 65.4%, 58.3%, 81.3%, and 74.1%, and that of P-gp was 57.7%, 70.8%, 65.6%, and 66.7%, respectively. HA117 expression was closely related to the clinical stage of HL (P=0.004) and to the International Prognostic Index score, mediastinal lesions, and clinical stages of NHL (P=0.01, 0.03, and 0.01). The expression of HA117 in WT was higher than in adjacent normal tissues, but there was no statistical significance (P=0.21). The positive expression of HA117 in NB was markedly higher than that in normal tissues (P=0.002), which closely associated with histologic type and lymph node metastasis (P=0.03 and 0.001). Spearman correlation analysis revealed that HA117 expression was not correlated with P-gp in these 4 tumors. This suggests that HA117 might be an important resistance gene in pediatric solid tumors. The mechanism underlying the resistance to all-trans retinoic acid conferred by HA117 is different from that of P-gp.
*Laboratory of Oncology
Departments of †Surgery
‡Ministry of Education Key Laboratory of Child Development and Disorders
§Key Laboratory of Pediatrics in Chongqing
∥Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Affiliated Children’s Hospital, Chongqing Medical University, Chongqing, China
Supported by the National Natural Science Foundation of China (No. 30330590) and in part by the National Natural Science Foundation of China (No. 39970768).
The authors declare no conflict of interest.
Reprints: Xianqing Jin, PhD, Laboratory of Oncology, Affiliated Children's Hospital, Chongqing Medical University, No.136, Zhongshan 2nd Road, Yuzhong District, Chongqing 86400014, China (e-mail: firstname.lastname@example.org).
Received September 5, 2012
Accepted February 20, 2013